TY - JOUR
T1 - Perspective
T2 - Humanized Pig Models of Bladder Cancer
AU - Segatto, Natália Vieira
AU - Bender, Camila Bonemann
AU - Seixas, Fabiana Kommling
AU - Schachtschneider, Kyle
AU - Schook, Lawrence
AU - Robertson, Noah
AU - Qazi, Aisha
AU - Carlino, Maximillian
AU - Jordan, Luke
AU - Bolt, Courtni
AU - Collares, Tiago
N1 - Publisher Copyright:
© Copyright © 2021 Segatto, Bender, Seixas, Schachtschneider, Schook, Robertson, Qazi, Carlino, Jordan, Bolt and Collares.
PY - 2021/5/17
Y1 - 2021/5/17
N2 - Bladder cancer (BC) is the 10th most common neoplasia worldwide and holds expensive treatment costs due to its high recurrence rates, resistance to therapy and the need for lifelong surveillance. Thus, it is necessary to improve the current therapy options and identify more effective treatments for BC. Biological models capable of recapitulating the characteristics of human BC pathology are essential in evaluating the effectiveness of new therapies. Currently, the most commonly used BC models are experimentally induced murine models and spontaneous canine models, which are either insufficient due to their small size and inability to translate results to clinical basis (murine models) or rarely spontaneously observed BC (canine models). Pigs represent a potentially useful animal for the development of personalized tumors due to their size, anatomy, physiology, metabolism, immunity, and genetics similar to humans and the ability to experimentally induce tumors. Pigs have emerged as suitable biomedical models for several human diseases. In this sense, the present perspective focuses on the genetic basis for BC; presents current BC animal models available along with their limitations; and proposes the pig as an adequate animal to develop humanized large animal models of BC. Genetic alterations commonly found in human BC can be explored to create genetically defined porcine models, including the BC driver mutations observed in the FGFR3, PIK3CA, PTEN, RB1, HRAS, and TP53 genes. The development of such robust models for BC has great value in the study of pathology and the screening of new therapeutic and diagnostic approaches to the disease.
AB - Bladder cancer (BC) is the 10th most common neoplasia worldwide and holds expensive treatment costs due to its high recurrence rates, resistance to therapy and the need for lifelong surveillance. Thus, it is necessary to improve the current therapy options and identify more effective treatments for BC. Biological models capable of recapitulating the characteristics of human BC pathology are essential in evaluating the effectiveness of new therapies. Currently, the most commonly used BC models are experimentally induced murine models and spontaneous canine models, which are either insufficient due to their small size and inability to translate results to clinical basis (murine models) or rarely spontaneously observed BC (canine models). Pigs represent a potentially useful animal for the development of personalized tumors due to their size, anatomy, physiology, metabolism, immunity, and genetics similar to humans and the ability to experimentally induce tumors. Pigs have emerged as suitable biomedical models for several human diseases. In this sense, the present perspective focuses on the genetic basis for BC; presents current BC animal models available along with their limitations; and proposes the pig as an adequate animal to develop humanized large animal models of BC. Genetic alterations commonly found in human BC can be explored to create genetically defined porcine models, including the BC driver mutations observed in the FGFR3, PIK3CA, PTEN, RB1, HRAS, and TP53 genes. The development of such robust models for BC has great value in the study of pathology and the screening of new therapeutic and diagnostic approaches to the disease.
KW - bladder cancer
KW - large animal model
KW - oncopig
KW - pig
KW - urothelial carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85107033630&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107033630&partnerID=8YFLogxK
U2 - 10.3389/fmolb.2021.681044
DO - 10.3389/fmolb.2021.681044
M3 - Article
C2 - 34079821
AN - SCOPUS:85107033630
SN - 2296-889X
VL - 8
JO - Frontiers in Molecular Biosciences
JF - Frontiers in Molecular Biosciences
M1 - 681044
ER -